Scott-Edil Pharmacia

What Scott-Edil Pharmacia does

Scott-Edil Pharmacia Ltd is a privately held Indian pharmaceutical manufacturer founded in 1996, headquartered in Chandigarh, with four WHO-GMP certified manufacturing facilities (three in Baddi, Himachal Pradesh and one in Chandigarh) and approximately 1,500 employees. The company produces more than 700 drug formulations spanning antibiotics, analgesics, anti-hypertensives, anti-diabetics, vitamin supplements, and nutraceuticals across dosage forms including tablets, capsules, injectables, oral liquids, ophthalmic solutions, gels, and hand sanitizers. Its specialized intellectual property includes Prussian Blue formulations (Pru-Decorp and Pru-Decorp MG) developed under DRDO's Technology Development Fund for radioactive cesium and thallium poisoning treatment, with CDSCO approval and collaboration from Skanttr Life Sciences and INMAS.

The company operates a five-pronged business model. First, contract manufacturing for multinational pharmaceutical companies including Abbott, Alembic, Cadila, Cipla, Lupin, Biocon, Wockhardt, and German Remedies. Second, institutional business winning Indian state, central, and defense (Army hospital) tenders. Third, direct export of formulations to 46-70+ countries across Eastern Europe, Africa, Middle East, Southeast Asia, Latin America, and Oceania, with active EU GMP pursuit. Fourth, domestic brand marketing through its Searle Interphar division distributing OTC products such as Voligesic Plus Gel and MultitasQue to retailers. Fifth, a retail pharmacy franchise (Scott Edil Pharmacy) launched in February 2022, currently four stores in Chandigarh offering generic medicines at 60-85% discounts versus branded equivalents. The company is founder-led under Chairman Balram Aggarwal and Managing Director Sanjeev Aggarwal, with no disclosed external investors and a bootstrapped ownership structure typical of mid-sized Indian family-owned pharma manufacturers.

Name

Scott-Edil Pharmacia

Legal name

Scott-Edil Pharmacia Ltd

Website

https://scott-edil.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Scott-Edil Pharmacia is a privately held Indian pharmaceutical manufacturer founded in 1996, operating four WHO-GMP plants producing 700+ formulations for multinational contract manufacturing clients, government tenders, exports to 46+ countries, and a retail pharmacy franchise.

Ownership category

akta.pro rank

Headquarters

HQ city

Chandigarh

HQ country

India

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Contract Manufacturing: Manufacturing pharmaceutical products for multinational companies such as Abbott, Alembic, Cadila, Cipla, Lupin, Biocon, Wockhardt and German Remedies. Company provides stellar facilities and transparent manufacturing practices with WHO-GMP compliance.
2. Direct Exports: Export of formulations to over 66 countries including Russia, Ukraine, Georgia, Iraq, Afghanistan, Kazakhstan, Philippines, Vietnam, Yemen, South Sudan, Nigeria, Zimbabwe, Sri Lanka, and others. Company is pursuing EU GMP certification for further global expansion.
3. Institutional Business: Regular wins of government tenders for supply of medicines at state and central levels. Competitive pricing and consistent quality have enabled supply to various army hospitals.
4. Marketing and Distribution (Searle Interphar): Marketing division brand Searle Interphar sells and promotes formulations through distributors and retailers. OTC products like Voligesic Plus Gel and Multitasque Multivitamin Capsules are popular branded products.
5. Pharmacy Franchise: Franchise model for retail pharmacies operating under Scott Edil Pharmacy brand. Founded in February 2022, stores offer generic medicines and OTC products at discounted prices up to 80% off market rates.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels5 records

Core offering

Scott-Edil Pharmacia is a pharmaceutical manufacturer producing over 700 drug formulations across multiple dosage forms (injections, tablets, capsules, oral liquids, gels, ophthalmic solutions, dry syrups, dietary supplements and hand sanitizers) at its four WHO-GMP certified manufacturing facilities. The company operates four business streams: contract manufacturing for multinational pharma companies, government/institutional supply, direct exports to 66+ countries, and domestic branded distribution through the Searle Interphar marketing division and Scott Edil Pharmacy retail franchise.

Product overview

Scott-Edil Pharmacia Ltd is a leading Indian pharmaceutical company offering a diverse portfolio of over 700 drug formulations across multiple therapeutic segments. The company operates through distinct divisions: its WHO-GMP certified manufacturing operations producing prescription pharmaceuticals (antibiotics, cardiovascular, antidiabetic, NSAIDs, nutritional supplements), its Searle Interphar marketing division for domestic distribution, and its Scott Edil Pharmacy retail franchise network. Key OTC products include Voligesic Plus Gel and Spray for pain relief, MultitasQue and MYC multivitamins, MyZinc supplements, and hand sanitizers. The company also developed specialized Prussian Blue formulations (Pru-Decorp, Pru-Decorp MG) as antidotes for radioactive poisoning under DRDO collaboration. Products are exported to over 46 countries globally through contract manufacturing arrangements with multinational pharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Brands

• Voligesic: Pain relief gel and spray products for muscle pain and inflammation
• MultitasQue
• MYC
• MyZinc
• Pru-Decorp
• Pru-Decorp MG

Products and services

• Voligesic Spray Fast-acting pain reliever spray for joints and muscles, available in 55gm spray form, sold under the Searle Interphar brand.
• Voligesic Plus Gel Topical NSAID gel for muscle pain and inflammation containing Diclofenac Diethylamine, Linseed Oil, Menthol, and Methyl Salicylate, available in 10gm, 30gm and 50gm sizes.
• Hand Sanitizer (5L / 500ml / 250ml / 100ml) WHO-approved hand sanitizer line in multiple pack sizes (5L, 500ml, 250ml, 100ml) containing Ethanol IP 70%, sold via the company e-commerce store and Searle Interphar network.
• MultitasQue Multivitamin Caplets Multivitamin caplet supplement containing Vitamin A, B-complex, C, D3, Zinc, Magnesium, and Grape Seed Extract for balanced nutrition.
• MYC Chewable Tablets Vitamin C and Zinc chewable supplement containing Ascorbic Acid, Sodium Ascorbate, and Zinc Citrate for immune system support.
• MyZinc Tablets Zinc dietary supplement tablet containing Zinc Sulphate Monohydrate IP 137.225mg (elemental zinc 50mg) for treating and preventing zinc deficiency.
• Pru-Decorp (Prussian Blue Insoluble Capsules) CDSO-approved Prussian blue insoluble capsules indicated as antidote for radioactive Cesium/Thallium poisoning (generic equivalent of USFDA-approved Radiogardase-Cs).
• Pru-Decorp MG (Prussian Blue + Magnesium Hydroxide Capsules) Combination Prussian Blue insoluble and Magnesium Hydroxide capsules indicated for rescue responders entering zones contaminated with radioactive or non-radioactive isotopes of Cesium and Thallium.
• Searle Interphar (Branded Marketing Division) Marketing division and trusted brand that sells and promotes Scott-Edil formulations (Voligesic Plus Gel, MultitasQue, etc.) through distributors and retailers across India.
• Scott Edil Pharmacy Franchise Retail pharmacy franchise operation offering generic medicines and OTC products at affordable prices (up to 80% off market rates); four stores operating in Chandigarh as of 2022.
• Pharmaceutical Contract Manufacturing Services WHO-GMP certified contract manufacturing services for multinational pharmaceutical companies producing branded formulations using Scott-Edil's multi-dosage-form manufacturing capacity.
• Pharmaceutical Export Services Direct export of generic pharmaceutical formulations to 66+ countries including Russia, Ukraine, Georgia, Iraq, Afghanistan, Kazakhstan, Philippines, Vietnam, Yemen, South Sudan, Nigeria, Zimbabwe, Sri Lanka and others; pursuing EU GMP certification for further expansion.

Quantifiable outcome

• Generic medicines offered at 60-85% discount compared to market branded equivalents
• +3 more outcomes

Named customers8 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eleven partnerships are on record, tiered core and major.

• Defence Research and Development Organisation (DRDO)coreStrategic or Co-development Partner · 1 January 2020Technology Development Fund project for development of Prussian Blue formulations as antidote for Radioactive Cesium/Thallium Poisoning. Project sanctioned in 2020 based on laboratory level research by INMAS.
• AbbottcoreStrategic or Co-development PartnerContract manufacturing alliance where Abbott utilizes Scott-Edil's WHO-GMP certified manufacturing facilities for pharmaceutical production.
• AlembiccoreStrategic or Co-development PartnerContract manufacturing alliance including acquisition of Alembic Pharma's Baddi facility in 2017, expanding manufacturing capacity.
• CadilacoreStrategic or Co-development PartnerContract manufacturing alliance for pharmaceutical products using Scott-Edil's manufacturing capabilities.
• CiplacoreStrategic or Co-development PartnerContract manufacturing alliance leveraging Scott-Edil's WHO-GMP facilities and quality standards.
• LupincoreStrategic or Co-development PartnerContract manufacturing partnership for pharmaceutical formulations.
• BioconcoreStrategic or Co-development PartnerStrategic manufacturing alliance with biotech company Biocon.
• WockhardtmajorStrategic or Co-development PartnerContract manufacturing alliance for pharmaceutical products.
• German RemediesmajorStrategic or Co-development PartnerContract manufacturing partnership.
• Skanttr Life SciencescoreTechnology or IntegrationCollaborator in development of Prussian Blue formulations. M/s Skanttr Life Sciences, Ahmedabad helped develop Prussian Blue Insoluble API and formulations, rendering India self-reliant.
• Institute of Nuclear Medicine and Allied Sciences (INMAS)coreTechnology or IntegrationDRDO's R&D laboratory in Delhi that conducted laboratory level research for Prussian Blue formulations. Provided technical handholding during development.

Scale indicators8 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Lupin: Major Indian pharmaceutical company with a broad generics portfolio, complex generics and global manufacturing footprint across multiple dosage forms. Comparable to Scott-Edil in therapeutic breadth, dosage-form coverage and global export reach; also a Scott-Edil contract manufacturing customer.
• Biocon: India-based biopharmaceutical and generics company operating formulations, biosimilars and APIs globally. Comparable on contract manufacturing scale and the CMO-style relationship Scott-Edil runs with multinational partners; Biocon is also one of Scott-Edil's contract-manufacturing customers.
• Cipla: One of India's largest pharmaceutical manufacturers with multi-therapy generic formulations and export operations spanning Africa, Asia and regulated markets. Directly comparable to Scott-Edil as a large Indian generic pharma player with diverse dosage forms and an institutional/CMO business; Scott-Edil is also a contract manufacturer for Cipla.
• Wockhardt: Indian pharmaceutical company with branded generics, APIs and exports focused on emerging markets (Russia/CIS, Africa, Asia). Highly comparable therapeutic mix and emerging-market export strategy; Wockhardt is also a contract-manufacturing customer of Scott-Edil.
• Alembic Pharmaceuticals: Indian generic pharma company with API and formulation manufacturing across multiple dosage forms and significant US generics presence. Highly comparable to Scott-Edil in product mix and therapeutic coverage, and historically tied through the 2017 Baddi facility acquisition and ongoing contract manufacturing relationship.
• Cadila Pharmaceuticals (Cadila/Zydus): Large Indian generic pharma manufacturer with strong formulations portfolio, domestic distribution and exports across emerging markets. Comparable to Scott-Edil across formulation breadth, CMO/institutional business and emerging-market export focus; also a contract manufacturing customer.

Emerging players

• Strides Pharma: Indian specialty generics manufacturer focused on complex generics, soft gels and emerging-market distribution. Comparable to Scott-Edil's emerging-market formulation export strategy and CMO-like operating model, though focused on narrower complex-generic niches.

Broad incumbents

• Abbott India: Subsidiary of global diversified healthcare major, manufacturing and marketing a broad pharmaceutical portfolio in India. A Scott-Edil CMO customer; comparable as a large Indian pharma player but with a much broader global, regulated-market footprint and parent-company backing.
• Aurobindo Pharma: One of India's largest generic pharmaceutical manufacturers with leading US generics presence and broad emerging-market exports. Comparable on formulation breadth and CMO/contract manufacturing scale, but at a vastly larger size and with deeper USFDA approvals.
• Piramal Pharma: Indian pharma major with contract development and manufacturing services (CDMO) across sterile injectables and oral solids. Comparable to Scott-Edil on the CMO/CDMO arm of the business, though materially larger and integrated with development services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/scottedilgroup

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scott-Edil Pharmacia